男人天堂久久,亚洲中文色欧另类欧美,四虎海外永久

Johnson & Johnson Full Year 2025 Financial Report Johnson & Johnson Johnson & Johnson posts steady 2025 growth with $94.2B revenue, driven by pharmaceuticals ($60.4B) and medical technology. Strong innovation and global performance set a positive outlook for 2026.
Axalta Full Year 2025 Financial Report Axalta Axalta reported a challenging 2025 as revenue fell 3% to $5.12 billion and net profit declined, while adjusted EBITDA hit a record high and cash flow strengthened amid cost controls and FX support.
AstraZeneca Full Year 2025 Financial Report AstraZeneca AstraZeneca reports 2025 revenue of $58.7B, led by strong oncology growth, a record China performance, and a catalyst-rich pipeline driving momentum into 2026 and beyond.
BMS Full Year 2025 Financial Report BMS Bristol Myers Squibb reports 2025 results with stable revenue, a sharp rebound in profitability, strong growth from new products, and resilient Eliquis sales reaching $14.4 billion despite patent pressures.
AbbVie Full Year 2025 Financial Report AbbVie AbbVie reports strong 2025 results: revenue rises 9% to $61.2B, driven by Skyrizi and Rinvoq. Profits grow, international markets expand, and innovation sets stage for 2026.
GSK Full Year 2025 Financial Report GSK GSK reported ￡32.7B revenue in 2025, up 4% YoY, driven by specialty medicines and vaccines. Core profit rose 7%, with strong R&D pipeline and steady global growth supporting 2026 outlook.
Merck Full Year 2025 Financial Report Merck Merck's 2025 performance shows 1% revenue growth, driven by strong sales of KEYTRUDA, new products like WINREVAIR, and growth in animal health. The company maintains cautious optimism for 2026 amid challenges like patent cliffs and currency fluctuations.
Eli Lilly Full Year 2025 Financial Report Eli Lilly Eli Lilly's 2025 results show a 45% revenue increase to $65.2B, driven by Mounjaro and Zepbound sales. With strong growth in profits and an optimistic 2026 outlook, the company continues to lead in metabolic diseases and oncology treatments.
Amgen Full Year 2025 Financial Report Amgen Amgen's 2025 revenue rose 10%, reaching $36.75B, driven by strong product sales and innovation. The company projects continued growth in 2026, with a focus on R&D, cost control, and shareholder returns.
AkzoNobel's Full Year 2025 Financial Report Financial statements AkzoNobel's 2025 financial report reveals a 5% decline in sales, but a 17% increase in net profit. The company highlights growth in China’s decorative paints and announces a merger with Axalta to strengthen its position in the coatings market.

<Pre12 3 4 5 6 7 8...15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a